Skip to content
lifestyle.presbycamp.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Kyowa Kirin
Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL
June 10, 2026
FDA Approves New Dosing Option for CRYSVITA® (burosumab-twza) in Adults With XLH
May 14, 2026
CRYSVITA® Now Publicly Reimbursed for the Treatment of Adults with XLH in Four Provinces and Federal Non-Insured Health Benefits Program
May 6, 2026
Kyowa Kirin 重掌羅卡替尼單抗的研發和商業化項目，展現出致力解決異位性皮膚炎高度未獲滿足醫療需求的堅定承諾
January 31, 2026
Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis
January 30, 2026